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 1  |   INTRODUCTION 
 Epithelial ovarian cancer is a highly lethal gynecologic malig-
nancy, and its incidence and mortality rates in Korea are in-
creasing. 1  The current standard of treatment includes primary 
debulking surgery (PDS) plus adjuvant platinum‐based chemo-
therapy for advanced ovarian cancer. 2  Recently, several Phase 3 
clinical trials have investigated whether rates of survival, post-
operative morbidity, and mortality after receiving neoadjuvant 
chemotherapy (NAC) followed by interval debulking surgery 
(IDS) are not inferior to those achieved with PDS in women 
with Stages III‐IV ovarian cancer. 3,4  Therefore, NAC, followed 
by IDS, is an alternative approach to treat advanced‐stage ovar-
ian cancer when complete resection cannot be achieved. 
 Received:  19 September 2018 |  Revised:  25 November 2018 |  Accepted:  13 December 2018 
 DOI: 10.1002/cam4.1956 
 O R I G I N A L  R E S E A R C H  
 Pretreatment lymphocytopenia is an adverse prognostic 
biomarker in advanced‐stage ovarian cancer 
 Yong Jae  Lee |  Young Shin  Chung |  Jung‐Yun  Lee  |  Eun Ji  Nam | 
 Sang Wun  Kim |  Sunghoon  Kim |  Young Tae  Kim 
 This is an open access article under the terms of the  Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited. 
 © 2019 The Authors.  Cancer Medicine published by John Wiley & Sons Ltd. 
 Department of Obstetrics and 
Gynecology ,  Institute of Women ’ s Life 
Medical Science ,  Yonsei University College 
of Medicine ,  Seoul ,  Korea 
 Correspondence 
 Jung‐Yun Lee, Department of Obstetrics 
and Gynecology, Institute of Women ’ s Life 
Medical Science, Yonsei University College 
of Medicine, Seoul, Korea. 
 Email:  jungyunlee@yuhs.ac 
 Funding information
 National Research Foundation 
of Korea ,  Grant/Award Number: 
 2017M3A9E8029714 
 Abstract 
 The aim of this study was to investigate the prognostic significance of lymphocytope-
nia in advanced‐stage ovarian cancer. We retrospectively reviewed 506 patients with 
advanced‐stage ovarian cancer at Yonsei Cancer Hospital. This study included two 
cohorts of patients: a neoadjuvant chemotherapy ( NAC ) group (N  =  247) and a pri-
mary debulking surgery ( PDS ) group (N  =  259). The absolute lymphocyte count was 
recorded before treatment. A receiver operating characteristic ( ROC ) curve analysis 
was used to determine the cutoff for defining lymphocytopenia in the  NAC cohort 
and followed by multivariate analysis. Subsequently, lymphocytopenia was assessed 
in the  PDS cohort by multivariate analysis. A further analysis was performed to eval-
uate the absolute lymphocyte count as a continuous variable. An absolute lymphocyte 
count of 1.49 × 109/L was determined as the cutoff for the  ROC curve analysis in the 
 NAC cohort, and the multivariate analysis revealed that lymphocytopenia was an in-
dependent prognostic factor for poor progression‐free survival ( PFS ) [hazard ratio 
( HR ), 1.50; 95% confidence interval ( CI ), 1.07‐2.11] and overall survival ( OS ) ( HR , 
2.02; 95%  CI , 1.21‐3.40). In the  PDS cohort, the multivariate analysis showed that 
lymphocytopenia was an independent prognostic factor for poor  PFS ( HR , 1.73; 95% 
 CI , 1.20‐2.49) and  OS ( HR , 1.87; 95%  CI , 1.27‐2.75). The absolute lymphocyte count 
was a significant factor when analyzed as a continuous variable in both the  NAC and 
 PDS cohorts. Pretreatment lymphocytopenia is an independent adverse prognostic 
factor in patients with advanced‐stage ovarian cancer. 
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 Clinical stage, histological subtypes and grade, residual 
tumor, the presence of ascites, performance status, and cancer 
antigen 125 (CA‐125) levels are all known prognostic factors 
in ovarian cancer. 5  In addition to these established prognostic 
factors, interest has been growing in evaluating the systemic 
inflammatory and immune responses to cancer cells repre-
sented by the levels of neutrophils, lymphocytes, platelets, 
and acute‐phase proteins. A previous study showed that the 
systemic inflammation initiated by cancer induces apoptosis 
and margination of white blood cells leading to an increase 
in the number of neutrophils and a decrease in the number of 
lymphocytes. 6  The absolute lymphocyte count is the number 
of lymphocytes circulating in peripheral blood, and devia-
tions in this count can be used to evaluate the host ’ s immune 
response during illness. 7  Preoperative lymphocytopenia has 
been suggested recently as a new independent prognostic 
factor for several solid tumors, such as renal, 8  bladder, 9  and 
colorectal cancer. 10  However, the prognostic significance of 
lymphocytopenia in ovarian cancer has not been evaluated. 
Lymphocytopenia may represent a type of cancer‐induced 
immune suppression that may limit the use of chemotherapy 
in cancer treatment. 11  
 To investigate the prognostic significance of pretreat-
ment lymphocytopenia, we chose a cohort of advanced‐
stage ovarian cancer patients treated with PDS followed by 
adjuvant chemotherapy and a separate cohort of advanced‐
stage ovarian cancer treated with NAC followed by IDS. 
 2  |   MATERIALS AND METHODS 
 The study was retrospective and included two cohorts of pa-
tients. There were 537 advanced‐stage ovarian cancer patients 
treated with NAC followed by IDS or PDS from 2006 to 2017 
in our institution. The patients with autoimmune disease or pa-
tients taking medication that could affect the immune function 
were excluded in both cohorts. We excluded 31 patients in this 
study. Of 31 patients, 26 patients had autoimmune disease in-
cluding thyroid disease, type 1 diabetes mellitus, and systemic 
sclerosis. Five patients were taking a medication with hepati-
tis. Finally, a total of 506 patients were included in the study. 
 The blood samples were collected in ethylenedi-
aminetetraacetic acid (EDTA) tubes and immediately sent for 
analysis. Hematologic parameters were counted by XN‐9000 
(Sysmex, Kobe, Japan) hematology analyzers. Absolute lym-
phocyte counts were calculated by multiplying the values of 
white blood cells by lymphocyte percentage. 
 2.1 |  NAC cohort 
 This cohort comprised 247 patients with pathologically 
confirmed epithelial ovarian cancer who had received at 
least one cycle of NAC at Yonsei Cancer Hospital between 
2006 and 2017. Before starting NAC, all patients were 
histologically or cytologically confirmed to have Stage 
III or Stage IV epithelial ovarian cancer according to the 
criteria of the International Federation of Gynecology 
and Obstetrics (FIGO). The diagnosis was reached via 
either laparoscopic or image biopsy samples or by using 
fine‐needle aspiration of a tumor site or ascites/effusion. 
The histological diagnoses were based on World Health 
Organization criteria, and all microscopic slides were 
reviewed by two experienced gynecologic pathologists. 
NAC was performed if at least one of the following three 
criteria were met: (a) pulmonary and/or hepatic parenchy-
mal metastases were observed on imaging studies before 
surgery, (b) the patient was medically inoperable, and/
or (c) optimal cytoreduction was not achievable because 
of a high tumor burden (Fagotti score ≥ 8) observed by 
diagnostic laparoscopy. 12  According to our institutional 
policy, IDS was preferred after three cycles of NAC. 
All patients received taxane and platinum combination 
chemotherapy. 
 During the period between the initial diagnosis and the 
initiation of NAC, all patients underwent at least two blood 
tests that included blood counts. This analysis used the lowest 
absolute lymphocyte count obtained during these tests. 
 2.2 |  PDS cohort 
 A total of 259 patients with pathology‐confirmed FIGO 
Stage III or IV ovarian cancer who underwent PDS at Yonsei 
Cancer Hospital between 2006 and 2014 were included in 
this cohort. 
 All underwent cytoreductive surgery and received post-
operative adjuvant chemotherapy. During the period between 
the initial diagnosis and the PDS, all patients underwent at 
least two blood tests that included blood counts. This analysis 
used the lowest absolute lymphocyte count obtained during 
these tests. 
 2.3 |  Surgical procedures for PDS/IDS 
 Standard surgical procedures included the sampling of free 
fluid or peritoneal washings for cytology; a thorough in-
spection of the abdomen and pelvis, including the upper ab-
dominal viscera, diaphragm, and retroperitoneal spaces; and 
hysterectomy, bilateral oophorectomy and omentectomy, 
pelvic/para‐aortic lymph node dissection, and appendectomy. 
If necessary, the surgery also included bowel resection, dia-
phragm or other peritoneal surface stripping, splenectomy, 
partial hepatectomy, partial gastrectomy, or partial cystec-
tomy with or without ureteroneocystostomy, cholecystec-
tomy, and/or distal pancreatectomy. 13  
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 2.4 |  Analysis 
 All patients’ medical records were reviewed retrospectively 
to collect clinical and laboratory data. The endpoints included 
progression‐free survival (PFS) and overall survival (OS), 
which were evaluated by RECIST (version 1.1). PFS was de-
fined as the interval between the dates of diagnosis and the 
first recurrence. OS was defined as the interval between the 
dates of diagnosis and death or the last follow‐up. Recurrence 
was defined as the date of the appearance of radiologically 
detected disease during a follow‐up examination. 
 Descriptive data are reported as the median (range) or fre-
quency (percentage). Categorical variables were compared 
with the chi‐square or Mann‐Whitney  U test and continuous 
variables with Student ’ s  t test. Survival analyses used the 
Kaplan‐Meier method, and the data were compared using 
a log‐rank test. A receiver operating characteristic (ROC) 
curve was generated and assessed to find the best cutoff 
point within an absolute lymphocyte count to use to predict 
survival based on detection of lymphocytopenia in the NAC 
cohort. Based on the area under the ROC curve (AUC), the 
optimal cutoff (Youden index) was selected to maximize the 
sum of the sensitivity and specificity in the NAC cohort. A 
Cox regression analysis was used to evaluate the association 
of the prognostic factors with survival, expressed as hazard 
ratios (HR) and 95% confidence intervals (CI). 
 We adjusted the following variables for multivariate anal-
ysis: age (NAC cohort: >55 or ≤55, PDS cohort: >58 or 
≤58), American Society of Anesthesiologists (ASA) score 
(1‐2 or 3‐4), absolute neutrophil count (≥1.49 × 10 9 /L or 
<1.49 × 10 9 /L), hemoglobin (≥12.0 g/dL or <12.0 g/dL), 
absolute lymphocyte count (≤7.5 × 10 9 /L or >7.5 × 10 9 /L), 
CA‐125 level (NAC cohort: ≤1715.3 U/mL or >1715.3 U/
mL, PDS cohort: ≤1791.7 U/mL or >1791.7 U/mL), FIGO 
stage (III or IV), histologic subtypes (HGSC or non‐HGSC), 
residual disease (none or any residual), chemotherapy reg-
imen (paclitaxel‐carboplatin or other), and cycles of total 
chemotherapy. Continuous variables such as age, absolute 
neutrophil count, hemoglobin, and CA‐125 were categorized 
according to median values. A second analysis evaluated the 
impact of the absolute lymphocyte count, absolute neutro-
phil count and hemoglobin, age, CA‐125 level, and cycles of 
total chemotherapy as continuous variables. For all analyses, 
the level of statistical significance was set to  P  <  0.05. The 
statistical analyses were performed with the SPSS statistical 
software (version 21.0; IBM Corp., Armonk, NY). 
 3  |   RESULTS 
 3.1 |  NAC cohort 
 The ROC curve analysis determined an absolute lymphocyte 
count of 1.49 × 10 9 /L as the optimal cutoff (Figure  S1 ). The 
area under the curve, sensitivity, and specificity were 0.67, 
76%, and 49%, respectively. The clinical characteristics of the 
two groups are shown in Table  1 . A total of 247 patients were 
included in this cohort; of these, 150 (60.7%) had lymphocy-
topenia and 97 (39.3%) did not. The two groups had signifi-
cantly different median hemoglobin levels ( P  =  0.015). We 
performed an analysis of the trend of absolute lymphocyte 
counts from 2006 to 2017 in NAC cohort and 2006 to 2014 
in PDS cohort. There was no significant trend of absolute 
lymphocyte counts according to year (Table  S1 ). 
 The median follow‐up duration was 31.2 months (range, 
1.6‐119.0 months). At the time of analysis, 99 patients (40.1%) 
had died, and 174 (70.4%) had recurrences. The Kaplan‐Meier 
curves for OS and PFS are shown in Figure  1 . Patients in the 
lymphocytopenia group had poorer PFS ( P  =  0.030) and OS 
( P  =  0.006) than those in the nonlymphocytopenia group. 
The median PFS was 16.3 months (range 2.1‐86.8 months) 
in the lymphocytopenia group and 20.2 months (range 
3.2‐108.8 months) in the nonlymphocytopenia group. 
The median OS was 45.6 months (range 3.2‐96.4 months) 
in the lymphocytopenia group and 89.2 months (range 
3.4‐119.0 months) in the nonlymphocytopenia group. 
 The results of the multivariate analysis of PFS and OS in 
patients treated with NAC are shown in Table  2 . The mul-
tivariate analysis showed that pretreatment lymphocytope-
nia was an independent prognostic factor associated with a 
higher risk of progression (HR, 1.50; 95% CI, 1.07‐2.11) and 
inferior OS (HR, 2.02; 95% CI, 1.21‐3.40). Under multivar-
iate analysis in a continuous variable model, the absolute 
lymphocyte count retained significance as a prognostic fac-
tor in recurrence (HR, 0.63; 95% CI, 0.46‐0.88) and OS (HR, 
0.31; 95% CI, 0.17‐0.56). The results of the univariate/mul-
tivariate analyses for all variables are in Tables  S2 and  S3 . 
 3.2 |  PDS cohort 
 The baseline characteristics of the cohort of patients treated 
with PDS are shown in Table  3 . This cohort had 259 patients; 
of these, 172 (66.4%) had lymphocytopenia. The ASA score, 
median hemoglobin level, and median absolute neutrophil 
count showed significant differences between the lymphocy-
topenia and the nonlymphocytopenia groups. 
 The median follow‐up duration was 54.3 months (range, 
0.5‐144.0 months). At the time of analysis, 171 patients (66.0%) 
had died, and 191 (73.7%) had recurrences. The Kaplan‐Meier 
curves for OS and PFS are shown in Figure  2 . Patients in the 
lymphocytopenia group had poorer PFS ( P  =  0.001) and OS 
( P  =  0.001) than those in the nonlymphocytopenia group. 
The median PFS was 17.0 months (range 0.5‐135.5 months) 
in the lymphocytopenia group and 29.0 months (range 
0.7‐139.8 months) in the nonlymphocytopenia group. The 
median OS was 52.6 months (range 0.5‐139.4 months) 
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in the lymphocytopenia group and 82.0 months (range 
0.7‐144.0 months) in the nonlymphocytopenia group. 
 The results of the multivariate analysis of PFS and OS in 
patients treated with PDS are shown in Table  4 . The multivar-
iate analysis showed that pretreatment lymphocytopenia was 
an independent prognostic factor associated with a higher risk 
of progression (HR, 1.73; 95% CI, 1.20‐2.49) and inferior OS 
(HR, 1.87; 95% CI, 1.27‐2.75). Under multivariate analysis in 
a continuous variable model, the absolute lymphocyte count 
retained significance as a prognostic factor for recurrence 
(HR 0.46; 95% CI, 0.32‐0.68) and OS (HR 0.42; 95% CI, 
0.28‐0.63). The results of the univariate/multivariate analyses 
for all variables are in Tables  S4 and  S5 . 
 4  |   DISCUSSION 
 In this study, we showed that pretreatment lymphocytope-
nia is an independent prognostic factor in advanced‐stage 
ovarian cancer patients treated with either NAC or PDS. 
Lymphocytopenia before initiation of NAC or PDS was found 
to independently correlate with PFS and OS. In addition, we 
 T A B L E  1   Baseline characteristics of patients treated with NAC (N = 247) 
 Characteristics 
 Absolute lymphocyte count 
≤1.49 × 10 9 /L (n = 150) 
 Absolute lymphocyte count 
>1.49 × 10 9 /L (n = 97)  P ‐value 
 Age, median (range), y  57 (31‐80)  60 (27‐79)  0.175 
 ASA score, n (%) 
 1  28 (18.7%)  13 (13.4%)  0.500 
 2  90 (60.0%)  57 (58.8%)  
 3  30 (20.0%)  26 (26.8%)  
 4  2 (1.3%)  1 (1.0%)  
 CA‐125 level, median (range), U/mL  1781.5 (44.3‐20685.7)  1509.0 (66.7‐17911.3)  0.161 
 Hemoglobin level, median (range), g/L  12.1   g/L (8.3‐16.3)  12.5   g/L (9.4‐15.7)  0.015 
 Absolute lymphocyte count, median (range), cells/L  1.09 × 10 9 /L (0.31‐1.47)  1.85 × 10 9 /L (1.50‐3.10)  <0.001 
 Absolute neutrophil count, median (range), cells/L  5.40 × 10 9 /L (0.66‐14.02)  5.15 × 10 9 /L (1.49‐36.52)  0.316 
 FIGO stage, n (%) 
 III  72 (48.0%)  40 (41.2%)  0.360 
 IV  78 (52.0%)  57 (58.8%)  
 Histologic type, n (%) 
 HGSC  137 (91.3%)  89 (91.8%)  0.986 
 Endometrioid  2 (1.3%)  1 (1.0%)  
 Mucinous  2 (1.3%)  2 (2.1%)  
 Others  9 (6.0%)  5 (5.2%)  
 Grading 
 1  5 (3.3%)  3 (3.1%)  0.121 
 2  23 (15.3%)  11 (11.3%)  
 3  100 (66.7%)  77 (79.4%)  
 Not available  22 (14.7%)  6 (6.2%)  
 Residual disease, n (%) 
 No  53 (35.3%)  45 (46.4%)  0.212 
 Any residual  82 (54.7%)  45 (46.4%)  
 Not available  15 (10.0%)  7 (7.2%)  
 Chemotherapy regimen, n (%) 
 Paclitaxel + carboplatin  113 (75.3%)  81 (83.5%)  0.286 
 Docetaxel + carboplatin  34 (22.7%)  14 (14.4%)  
 Paclitaxel + carboplatin + bevacizumab  3 (2.0%)  2 (2.1%)  
 Cycles of total chemotherapy, median (range)  8 (4‐12)  8 (3‐12)  0.225 
 ASA, American Society of Anesthesiologists; CA‐125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; HGSC, high‐grade serous 
carcinoma; NAC, neoadjuvant chemotherapy. 
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showed that the absolute lymphocyte count was a significant 
adverse factor as a continuous variable in both the NAC and 
PDS cohorts, demonstrating that the magnitude of lymphocy-
topenia correlates with an inferior survival outcome. 
 Lymphocytopenia, which is frequently observed in ovar-
ian cancer, 14  may possibly reflect a state of tumor‐induced 
immune suppression. Although the actual mechanisms of 
tumor‐induced immune suppression are not fully known, 
the possibilities include that this suppression is the result of 
impaired homeostasis of lymphocytes and the consequence 
of chemokines and cytokines produced by the tumor micro-
environment. Lymphocyte homeostasis requires the pres-
ence of dendritic cells and function of dendritic cells. 15  The 
differentiation of dendritic cells is impaired by the over-
production of numerous cytokines and mediators such as 
interleukin‐6 and transforming growth factor β; this over-
production is caused by the tumor microenvironment. 16  
Lymphocytes of cancer also produce proapoptotic ligands 
such as Fas ligand, tumor necrosis factor, and programmed 
death‐1 ligand‐1 that produce inhibitory signals to suppress 
the cytotoxic activity of T cells. 17  Changes in the cytokines 
provoke subtle modifications of the tumor microenviron-
ment that interfere with the ability of the immune system to 
coordinate and efficiently control the tumor. 
 Recently, pretreatment lymphocytopenia has been sug-
gested as an adverse prognostic factor in several solid tumors. 
Jang et al 18  demonstrated that lymphocytopenia at diagnosis 
was a significant factor for poor survival outcomes in patients 
with primary central nervous system lymphoma. Joseph et al 
showed that pretreatment lymphocytopenia is an indepen-
dent adverse prognostic factor in both muscle‐invasive and 
advanced bladder cancer. In addition, the study showed that 
the magnitude of lymphocytopenia correlates with inferior 
outcomes. 9  
 Lymphocytopenia may reflect a state of immune sup-
pression, which also diminishes the effect of chemother-
apy. 10  Ceze et al showed that the objective response rate 
was significantly lower in lymphocytopenia patients than 
in other colorectal cancer patients receiving chemother-
apy (12.5% vs 40.2%;  P = 0.004). 10  There are several dis-
tinct mechanisms by which chemotherapy can modify the 
interactions between cancer cells and host immunity. 19  
Chemotherapy triggers cancer cell death, which restores or 
enhances the expression of cancer antigens and increases 
their susceptibility to attack from immune cells. 19  Despite 
the many studies on tumor‐induced immune suppression as 
a prognostic factor, the association between tumor‐induced 
 F I G U R E  1   Kaplan‐Meier curves of progression‐free (A) survival and overall survival (B) stratified by lymphocytopenia in patients treated 
with  NAC .  NAC , neoadjuvant chemotherapy 
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 T A B L E  2   Multivariate analyses for progression‐free and overall 
survival using a Cox proportional hazards model with categorical 
variables and continuous variables in patients treated with NAC 
 Variables 
 PFS  OS 
 HR (95% CI)  HR (95% CI) 
 Absolute lymphocyte count (Categorical variables  a ) 
 ≥1.49 × 109/L  1  1 
 <1.49 × 10 9 /L  1.50 (1.07‐2.11)  2.02 (1.21‐3.40) 
 Absolute lymphocyte count 
(Continuous variables  b ) 
 0.63 (0.46‐0.88)  0.31 (0.17‐0.56) 
 ASA, American Society of Anesthesiologists; CI, confidence interval; FIGO, 
International Federation of Gynecology and Obstetrics; HR, hazard ratio; NAC, 
neoadjuvant chemotherapy; PFS, progression‐free survival; OS, overall survival. 
  a The multivariate analysis was adjusted for categorical variables (age, ASA score, 
hemoglobin, absolute neutrophil count, CA‐125 level, FIGO stage, histology, re-
sidual disease after IDS, chemotherapy regimen, cycles of total chemotherapy).   
  b The multivariate analysis was adjusted for continuous variables (age, hemoglo-
bin, absolute neutrophil count, CA‐125 level, cycles of total chemotherapy) and 
categorical variables (ASA score, FIGO stage, histology, residual disease after 
IDS, chemotherapy regimen).   
   | 569LEE ET AL.
immune suppression and the status of the tumor microenvi-
ronment remains unclear. Tumor‐induced alterations in the 
differentiation of dendritic cells impair lymphocyte homeo-
stasis and induce lymphocytopenia. Furthermore, dendritic 
cells attracted into the ovarian cancer microenvironment 
promote T cells to release large amounts of interleukin‐10, 
which prevents local T‐cell activation. 20  Dendritic cells me-
diate immune suppression in the tumor microenvironment 
of ovarian cancer by suppressing T‐cell immunity through 
upregulation of B7‐H1 21  and programmed cell death‐1. 22  
The immune response of the tumor microenvironment to 
ovarian cancer has a significant influence on clinical out-
comes. 23  Previous studies showed that the presence of 
CD+8 tumor‐infiltrating lymphocytes is associated with 
good survival outcomes. 24,25  However, Milne et al failed 
to find an association between absolute lymphocyte counts 
and CD8+ and CD20+ tumor‐infiltrating lymphocytes. 26  
They reported that absolute lymphocyte count seems to 
 T A B L E  3   Baseline characteristics of patients treated with PDS (N = 259) 
 Characteristics 
 Absolute lymphocyte count 
≤1.49 × 10 9 /L (n = 172) 
 Absolute lymphocyte count 
>1.49 × 10 9 /L (n = 87)  P ‐value 
 Age, median (range), y  55 (22‐83)  54 (27‐83)  0.609 
 ASA score, n (%) 
 1  71 (41.3%)  59 (67.8%)  0.001 
 2  82 (47.7%)  24 (27.6%)  
 3  18 (10.5%)  4 (4.6%)  
 Not available  1 (0.6)  0 (0%)  
 CA‐125 level, median (range), U/mL  930.1 (21.5‐30008.8)  624.8 (12.1‐12000.0)  0.090 
 Hemoglobin level, median (range), g/L  11.7   g/L (6.6‐16.7)  12.5   g/L (9.9‐14.0)  <0.001 
 Absolute lymphocyte count, median (range), cells/L  1.05 × 10 9 /L (0.23‐1.48)  1.84 × 10 9 /L (1.49‐3.05)  <0.001 
 Absolute neutrophil count, median (range), cells/L  6.48 × 10 9 /L (2.16‐21.51)  5.07 × 10 9 /L (2.04‐14.21)  <0.001 
 FIGO stage, n (%) 
 III  122 (70.9%)  65 (74.7%)  0.521 
 IV  50 (29.1%)  22 (25.3%)  
 Histologic type, n (%) 
 HGSC  135 (78.5%)  71 (81.6%)  0.663 
 Endometrioid  11 (6.4%)  6 (6.9%)  
 Mucinous  6 (3.5%)  4 (4.6%)  
 Others  20 (11.6%)  6 (6.9%)  
 Grading 
 1  12 (7.0%)  8 (9.2%)  0.481 
 2  64 (37.2%)  30 (34.5%)  
 3  80 (46.5%)  45 (51.7%)  
 Not available  16 (9.3%)  4 (4.6%)  
 Residual disease, n (%) 
 No  19 (11.0%)  7 (8.0%)  0.739 
 Any residual  119 (69.2%)  63 (72.4%)  
 Not available  34 (19.8%)  17 (19.5%)  
 Chemotherapy regimen, n (%) 
 Paclitaxel + carboplatin  128 (74.4%)  66 (75.9%)  0.776 
 Intraperitoneal  19 (11.0%)  9 (10.3%)  
 Docetaxel + carboplatin  17 (9.9%)  10 (11.5%)  
 Other  3 (1.7%)  0 (0%)  
 Not available  5 (2.9%)  2 (2.3%)  
 Cycles of total chemotherapy, median (range)  6 (1‐12)  6 (1‐9)  0.117 
 ASA, American Society of Anesthesiologists; CA‐125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; HGSC, high‐grade serous 
carcinoma; PDS, primary debulking surgery. 
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be not associated with the presence of tumor‐infiltrating 
lymphocytes. 
 Moreover, pretreatment lymphocytopenia can be a pre-
dictive biomarker to identify patients suitable for treatment 
to restore antitumor immunity in advanced‐stage ovarian 
cancer . In a retrospective analysis of over 167 adult patients 
treated with pembrolizumab or nivolumab for solid tumors, 
pretreatment and persistent lymphocytopenia during therapy 
were found to be correlated with unfavorable outcomes but 
also with less likelihood of immune‐related adverse events. 27  
Because blood‐based biomarkers have not been actively de-
veloped, further study is needed to determine whether less 
invasive and relatively easy blood‐based biomarkers can re-
veal the status of a tumor microenvironment. 
 If tumor‐associated immune suppression is a driver of 
cancer progression and of a poor response to chemother-
apy, therapeutic strategies directed toward the restoration of 
antitumor immunity may improve the outcome. Administration 
of IL‐2 causes a transient increase in absolute lymphocyte 
counts, which has been associated with tumor response in 
metastatic melanoma. 28  IL‐7 can also be used to increase 
lymphocytes (peripheral CD4+ and CD8+ T cells), resulting 
in immunomodulatory effects on T cells. 29  
 This study has several limitations. The median follow‐up 
period was only 31.2 months in patients treated with NAC. 
Furthermore, this study design was a retrospective review of 
medical records, which depended on medical records or docu-
mentation and avoided potential recall bias. The strength of this 
study is that the optimal cutoff to define lymphocytopenia was 
calculated in the NAC cohort, and this optimal cutoff value was 
subsequently applied to the PDS cohort to demonstrate the in-
dependent prognostic effect of pretreatment lymphocytopenia. 
 In conclusion, pretreatment lymphocytopenia is a conve-
nient and independent prognostic factor for advanced‐stage 
ovarian cancer patients. It may be associated with cancer‐
induced immune suppression during tumor progression. 
Immuno‐oncologic agents restoring normal lymphocyte ho-
meostasis may hold considerable promise in the treatment of 
advanced‐stage ovarian cancer. 
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 F I G U R E  2   Kaplan‐Meier curves of progression‐free (A) survival and overall survival (B) stratified by lymphocytopenia in patients treated 
with  PDS .  PDS , primary debulking surgery 
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 T A B L E  4   Multivariate analyses for progression‐free and overall 
survival using a Cox proportional hazards model with categorical 
variables and continuous variables in patients treated with PDS 
 Variables 
 PFS  OS 
 HR (95% CI)  HR (95% CI) 
 Absolute lymphocyte count (Categorical variables  a ) 
 ≥1.49 × 10 9 /L  1  1 
 <1.49 × 10 9 /L  1.73 (1.20‐2.49)  1.87 (1.27‐2.75) 
 Absolute lymphocyte count 
(Continuous variables  b ) 
 0.46 (0.32‐0.68)  0.42 (0.28‐0.63) 
 ASA, American Society of Anesthesiologists; CI, confidence interval; FIGO, 
International Federation of Gynecology and Obstetrics; HR, hazard ratio; OS, 
overall survival; PDS, primary debulking surgery; PFS, progression‐free 
survival. 
  a The multivariate analysis was adjusted for categorical variables (age, ASA score, 
hemoglobin, absolute neutrophil count, CA‐125 level, FIGO stage, histology, re-
sidual disease after IDS, chemotherapy regimen, cycles of total chemotherapy).   
  b The multivariate analysis was adjusted for continuous variables (age, hemoglo-
bin, absolute neutrophil count, CA‐125 level, cycles of total chemotherapy) and 
categorical variables (ASA score, FIGO stage, histology, residual disease after 
IDS, chemotherapy regimen).   
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